Hansa Biopharma attended Morgan Stanley’s Global Healthcare Conference on September 14-15. A replay of the fireside chat between CEO Soren Tulstrup and analyst James Quigley can be accessed here.

View Webcast

Erik Penser Bank has initiated coverage of Hansa Biopharma with a buy recommendation

Read report

Hansa Biopharma reported its H1’21 Earnings on July 15, 2021. Access to the report and conference call here.

Read report and view webcast

Updated company collected consensus available from 11 banks and research institutions

Read more

Hansa Biopharma achieved reimbursement in the Netherlands of Idefirix® as desensitization treatment for highly sensitized kidney transplant patients. Beyond the Netherlands Hansa has also obtained reimbursement/market access agreement in Sweden and Finland

Read press release

The U.S. trial design for a randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients was announced in late June 2021

Read more

H.C. Wainwright has initiated coverage of Hansa Biopharma with a buy recommendation

Full analyst coverage

SEB is hosting a KOL Expert call on Gene Therapy with Prof. Thomas Sejersen MD, PhD, KI and Lena Winstedt PhD, Global Gene Therapy Franchise Lead, Hansa Biopharma. The call is hosted by SEB analyst Christopher Uhde. The call is restricted to clients of SEB

See calendar

Hansa Biopharma at a Glance

Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.



Our Equity Story

Imlifidase works
Targeting rare diseases with a high unmet medical need
Addresses a clear unmet need
Commercialize Idefirix® in first markets and indications
Well positioned for commercial success
Evolution into a fully integrated biopharmaceutical company
Rich pipeline
Leveraging our proprietary antibody cleaving enzyme technology

Learn More

Latest Financial Results

View All Results
View all news

Latest News

View all events

Upcoming Events

Milestones and near-term news flow

Near Term News Near Term News

For any investor related inquiries, please contact IR@hansabiopharma.com